Although programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) are well known immune checkpoints that guard against autoimmunity under physiological conditions, these immune checkpoints can also prevent the anti-cancer efficiency of endogenous or therapeutically applied exogenous modified T cells. Here, CTLA4 is linked to cancer.